4D Molecular Therapeutics, Inc.
FDMT
$14.22
-$0.41-2.80%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | 24.09% | -96.42% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 24.09% | -96.42% | |||
| Cost of Revenue | 5.08% | 12.99% | |||
| Gross Profit | -4.15% | -324.54% | |||
| SG&A Expenses | 7.16% | -8.46% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 5.40% | 9.10% | |||
| Operating Income | -4.63% | -596.93% | |||
| Income Before Tax | -6.07% | -454.49% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -6.07% | -454.49% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -6.07% | -454.49% | |||
| EBIT | -4.63% | -596.93% | |||
| EBITDA | -4.69% | -551.32% | |||
| EPS Basic | -2.74% | -432.85% | |||
| Normalized Basic EPS | -2.74% | -431.27% | |||
| EPS Diluted | -2.74% | -432.85% | |||
| Normalized Diluted EPS | -2.74% | -431.27% | |||
| Average Basic Shares Outstanding | 3.24% | 6.49% | |||
| Average Diluted Shares Outstanding | 3.24% | 6.49% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||